SPONSOR
Kirby Institute
Total Trials
4
Recruiting
4
Phases
Phase 3, Phase 4
Conditions studied: COVID-19Hepatitis COnchocerciasisAscaris Lumbricoides InfectionTrichuris Trichiura; InfectionHookworm InfectionsScabiesHepatitis B
Kirby Institute is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including COVID-19, Hepatitis C, Onchocerciasis, Ascaris Lumbricoides Infection.
The trial portfolio spans Phase 3, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Kirby Institute
How many clinical trials has Kirby Institute sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Kirby Institute, of which 4 are actively recruiting participants. These trials cover conditions including COVID-19, Hepatitis C, Onchocerciasis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Kirby Institute research focus on?
Kirby Institute clinical trials span COVID-19, Hepatitis C, Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, and additional conditions. The research pipeline includes Phase 3, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Kirby Institute clinical trial?
To participate in a Kirby Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Kirby Institute trials with current recruitment status updated daily.
Clinical Trials by Kirby Institute
NCT05415267 Phase 3
Recruiting
Immunosuppression and COVID-19 Boosters
COVID-19
NCT03685045
Recruiting
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
Hepatitis C
NCT07145736 Phase 4
Recruiting
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
Onchocerciasis
NCT04914611
Recruiting
Real World Assessment of People Living With Chronic Hepatitis B in Australia
Hepatitis B
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology